Group 1 - The company, JiuZhiTang Co., Ltd., will participate in the 2025 Hunan Province Listed Companies Investor Online Reception Day to enhance interaction with investors [1][2] - The event will be held online on September 19, 2025, from 15:40 to 17:00, allowing investors to engage with the company's executives regarding development strategies and operational status [1][3] - Investors can participate through the "Panorama Roadshow" website, WeChat public account, or by downloading the Panorama Roadshow APP [1]

公告文件 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，九芝堂股份有限公司（以下简称"公司"） 将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司联合举办 的 2025 年湖南辖区上市公司投资者网上集体接待日活动，现将相关事项公告如 下： 证券代码：000989 证券简称：九芝堂 公告编号：2025-066 九芝堂股份有限公司 关于参加 2025 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，投资者网上在线互动时间为 2025 年 9 月 19 日（星期五） 15:40-17:00。届时公司高管将在线就公司发展战略、经营状况等投资者关心的 问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告。 九芝堂股份有限公司董事会 2025 年 9 月 13 日 九芝堂股份有限公司 1 ...

Market Overview - On September 12, the Chinese medicine sector declined by 0.56%, with Qianjin Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 10.25, up 3.64% on a trading volume of 228,400 shares and a turnover of 230 million yuan [1] - Jiuzhitang (000989) closed at 10.91, up 2.83% with a trading volume of 212,800 shares and a turnover of 233 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.07, up 2.48% with a trading volume of 4,321,600 shares and a turnover of 891 million yuan [1] - Conversely, significant decliners included: - Qianjin Pharmaceutical (600479) closed at 11.05, down 1.60% with a trading volume of 115,400 shares and a turnover of 128 million yuan [2] - Jianmin Group (600976) closed at 42.45, down 1.12% with a trading volume of 18,100 shares and a turnover of 77 million yuan [2] - Hansen Pharmaceutical (002412) closed at 6.74, down 1.03% with a trading volume of 133,300 shares and a turnover of 89 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 642 million yuan from institutional investors, while retail investors saw a net inflow of 448 million yuan [2] - The following stocks had notable capital flows: - Kangmei Pharmaceutical had a net inflow of 65.97 million yuan from institutional investors, but a net outflow of 14.99 million yuan from retail investors [3] - Jiuzhitang saw a net inflow of 33.21 million yuan from institutional investors, with a net outflow of 16.66 million yuan from retail investors [3] - Wanbangde had a net inflow of 30.43 million yuan from institutional investors, but also faced a net outflow of 19.37 million yuan from retail investors [3]

章程附件 九芝堂股份有限公司 股东会议事规则 （2025 年修订） (2001 年 4 月 27 日 2000 年年度股东大会通过； 2001 年 12 月 27 日 2000 年第 2 次临时股东大会修正； 2002 年 5 月 9 日 2002 年年度股东大会修正； 2003 年 5 月 9 日 2002 年年度股东大会修正； 2005 年 6 月 28 日 2005 年第 1 次临时股东大会修正； 2006 年 9 月 2 日 2006 年第 3 次临时股东大会修订； 2007 年 11 月 7 日 2007 年第 5 次临时股东大会修正； 2014 年 2 月 28 日 2014 年第 1 次临时股东大会修正； 2016 年 1 月 15 日 2016 年第 1 次临时股东大会修正； 2016 年 5 月 12 日 2015 年年度股东大会修正； 2017 年 5 月 11 日 2016 年年度股东大会修正； 2017 年 11 月 2 日 2017 年第 1 次临时股东大会修正； 2018 年 1 月 18 日 2018 年第 1 次临时股东大会修正； 2019 年 5 月 29 日 2018 年年 ...

公司章程 九芝堂股份有限公司章程 （2025 年修订） （1999 年 11 月 8 日第 1 次临时股东大会会议通过； 2000 年 6 月 5 日第 1 次临时股东大会修正； 2001 年 12 月 27 日第 2 次临时股东大会修正； 2003 年 5 月 9 日 2002 年年度股东大会修正； 2003 年 6 月 25 日 2003 年第 1 次临时股东大会修正； 2004 年 4 月 22 日 2003 年度股东大会修正； 2005 年 4 月 4 日 2004 年股东大会修正； 2005 年 6 月 28 日 2005 年第 1 次临时股东大会修正； 2006 年 4 月 19 日 2005 年年度股东大会修正； 2006 年 9 月 2 日 2006 年第 3 次临时股东大会修订； 2007 年 8 月 16 日 2007 年第 3 次临时股东大会修正； 2007 年 11 月 7 日 2007 年第 5 次临时股东大会修正； 2008 年 9 月 19 日 2008 年第 1 次临时股东大会修正； 2009 年 4 月 22 日 2008 年年度股东大会修正； 2010 年 1 月 15 日 ...

公告资料 证券代码：000989 证券简称：九芝堂 公告编号：2025-065 九芝堂股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）现场会议召开时间：2025 年 9 月 10 日（星期三）下午 14:30 （2）网络投票时间： 通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时 间为 2025 年 9 月 10 日上午 9:15—9:25，9:30—11:30，下午 13:00—15:00； 通过深交所互联网投票系统投票的具体时间为：2025 年 9 月 10 日上午 9:15 至下午 15:00 的任意时间。 （3）召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 （4）现场会议召开地点：九芝堂股份有限公司管理中心第一会议室（北京 市朝阳区朝阳体育中心东侧路甲 518 号 A 座） （5）召集人：公司董事会 （6）主持 ...

湖南启元律师事务所 关于九芝堂股份有限公司 2025年第二次临时股东大会的 法律意见书 1 致：九芝堂股份有限公司 湖南启元律师事务所（以下简称"本所"）接受九芝堂股份有限公司（以下简 称"公司"）的委托，指派本所律师出席了公司 2025 年第二次临时股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员及 召集人的资格、表决程序和表决结果的合法有效性进行律师见证，并发表法律意 见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）等我国现行法律法规、规范性 文件以及《九芝堂股份有限公司章程》（以下简称"《公司章程》"）等有关规定 出具本法律意见书。 本所及本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、 准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 （二）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律 ...

Core Viewpoint - The stock price of Jiuzhitang has shown significant fluctuations in 2023, with a year-to-date increase of 38.85% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 10, Jiuzhitang's stock price rose by 2.21% to 10.64 CNY per share, with a trading volume of 1.22 billion CNY and a turnover rate of 1.67% [1] - The stock has experienced a 2.65% decline over the last five trading days and a 4.40% decline over the last twenty trading days, while it has increased by 19.69% over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Jiuzhitang reported a revenue of 1.265 billion CNY, a year-on-year decrease of 24.71%, and a net profit attributable to shareholders of 144 million CNY, down 29.71% year-on-year [3] - The company has distributed a total of 4.364 billion CNY in dividends since its A-share listing, with 935 million CNY distributed in the last three years [4] Group 3: Shareholder Information - As of June 30, 2025, Jiuzhitang had 50,500 shareholders, an increase of 25.14% from the previous period, with an average of 13,739 circulating shares per shareholder, a decrease of 20.09% [3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [4] Group 4: Business Overview - Jiuzhitang, established on May 12, 1999, and listed on June 28, 2000, is primarily engaged in the research, production, and sales of traditional Chinese medicine and biopharmaceuticals, with a revenue composition of 50.27% from prescription drugs and 46.11% from OTC products [2]

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 13.66 CNY [4][12]. Core Views - The company's performance in the first half of 2025 was under pressure, with a revenue of 1.265 billion CNY, a year-on-year decrease of 24.71%, and a net profit of 144 million CNY, down 29.71% [1][2]. - The pharmaceutical industrial sector is facing short-term challenges, but marketing reforms and new product development are expected to support long-term growth [2][3]. - The company is advancing its research projects, particularly in the stem cell drug market, which shows significant potential [3]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 1.265 billion CNY, a decrease of 24.71% year-on-year, and a net profit of 144 million CNY, down 29.71% [1]. - The second quarter of 2025 saw a revenue of 459 million CNY, a decline of 23.52%, and a net profit of 27 million CNY, down 54.58% [1]. Business Segments - The pharmaceutical industrial segment generated 1.229 billion CNY in revenue, down 25.06%, while the pharmaceutical commercial segment brought in 33 million CNY, down 3.12% [2]. - The OTC series revenue was 583 million CNY, a decrease of 36.05%, and the prescription drug series revenue was 636 million CNY, down 10.67% [2]. Marketing and R&D Initiatives - The company is implementing marketing reforms, including optimizing pricing policies and enhancing online and offline collaboration [2]. - Several R&D projects are progressing, including clinical trials for stem cell treatments, which are expected to contribute to long-term growth [3]. Future Projections - Revenue projections for 2025-2027 are estimated at 2.417 billion CNY, 2.629 billion CNY, and 2.887 billion CNY, respectively, with corresponding net profits of 224 million CNY, 292 million CNY, and 366 million CNY [8][10]. - The company anticipates a gradual recovery starting in 2026, with expected growth rates of 1.9%, 8.8%, and 9.8% for revenue [10][12].

Core Viewpoint - The company Jiuzhitang is advancing its research in stem cell therapy, particularly focusing on a new drug for treating Autism Spectrum Disorder (ASD) using human bone marrow mesenchymal stem cells, marking a significant milestone in clinical trials in China [1][2]. Group 1: Clinical Trial Developments - Jiuzhitang's subsidiary, Beijing Meike, has received ethical approval to initiate clinical trials for its human bone marrow mesenchymal stem cell injection project, specifically targeting ASD [1][2]. - The clinical trial for the stem cell injection has been approved by the National Medical Products Administration, making it the first of its kind in China for treating ASD [2]. Group 2: Product and Market Potential - The human bone marrow mesenchymal stem cell injection is classified as a Class 1 new drug and is aimed at treating Autism Spectrum Disorder, a complex neurodevelopmental disorder with no approved medications in China [2]. - Jiuzhitang is also making progress in other projects, including YB209, an innovative anticoagulant drug, and YB211, a new antibiotic targeting drug-resistant bacterial infections, both of which show promising market potential [3]. Group 3: Infrastructure and Recognition - Beijing Meike has established a large-scale stem cell drug research and production facility that meets GMP standards in China, the US, and the EU, positioning itself as a leading enterprise in the stem cell field in China [4].